in the development of a globally relevant, best-in-class network for early phase clinical research in diverse populations."

The objective of a typical early phase study is to provide information about the dosing, safety, and toxicity of a drug by giving it to a relatively small number of healthy people and capturing pharmacokinetic and other basic data, including patient-reported adverse events. By studying early compounds in small numbers of patients with a specific disease, rather than in only healthy volunteers, using proteomics, metabolomics, advanced imaging, and hemodynamic monitoring, MDRI will make significant insights at an earlier point in the clinical trials process.

Under the terms of the agreement, Medanta, a 1,500-bed institute founded by Trehan, will fund the creation and operation of the facility, with Duke providing scientific, clinical research, and operational expertise. Medanta and Duke will share joint oversight over implementation and management of the unit, and ensure adherence to the highest ethical standards and transparency.

A six-member MDRI board will include Califf, Sundy and Mr. Michael Sledge, chief financial officer of DTMI, as well as Trehan, Mittal and Virmani.

###